Bortezomib in Treating Patients With Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with
myelodysplastic syndromes.